DOI:
10.1055/s-00000125
Senologie - Zeitschrift für Mammadiagnostik und -therapie
LinksSchließen
Referenz
Di Leo A, Ciruelos E, Janni W. et al.
BELLE‑3: A phase III study of the panphosphatidylinositol 3-kinase (PI3K) inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced/ metastatic breast cancer (BC) pretreated with aromatase inhibitors (AIs) and refractory to mTOR inhibitor (mTORi)-based treatment. ASCO Annual Meeting.
2015 ; Chicago, Il; Abstract TPS626
Für die Inhalte der Internetseiten anderer Anbieter übernehmen wir keine Verantwortung.